pentobarbital will lessen the extent or outcome of gefitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will minimize the level or outcome of alosetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Unidentified.
pentobarbital will reduce the level or outcome of midazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
fentanyl intranasal and pentobarbital equally raise sedation. Stay clear of or Use Alternate Drug. Limit use to clients for whom alternative treatment method selections are insufficient
pentobarbital will lessen the level or effect of isradipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unknown.
pentobarbital will minimize the level or effect of solifenacin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
pentobarbital will minimize the level or impact of elagolix by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
lasmiditan, pentobarbital. Possibly improves effects of the opposite by sedation. Use Warning/Watch. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in scientific studies. Lasmiditan may induce sedation, in addition to other cognitive and/or neuropsychiatric adverse reactions.
Check Intently (1)pentobarbital will lower the level or impact of fentanyl by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Intently. Coadministration of fentanyl with CYP3A4 inducers could lead on to a lower in fentanyl plasma concentrations, deficiency of efficacy or, possibly, advancement of the withdrawal syndrome in the client who may have designed physical dependence to fentanyl. Following halting a CYP3A4 inducer, since the effects on the inducer decline, the fentanyl plasma focus will raise which could raise or extend equally the therapeutic and adverse effects.
pentobarbital will read more lessen the extent or impact of mavacamten by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will minimize the level or impact of fentanyl transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead on to some lower in fentanyl plasma concentrations, not enough efficacy or, perhaps, development of a withdrawal syndrome inside of a client who has created physical dependence to fentanyl.
pentobarbital will lower the extent or influence of fludrocortisone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
With therapeutic doses of TCAs, barbiturates boost metabolism and reduce blood concentrations of TCAs.
pentobarbital will decrease the level or impact of zaleplon by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Not known.